Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
10 affiliations
- 1SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy.
- 2Hospital Pharmacy, AOU Maggiore della Carità, Novara, Italy.
- 3Dermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
- 4SSD Dermatologia, AO Santa Croce e Carle Hospital, Cuneo, Italy.
- 5SS Dermatologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- 6UO Dermatologia, Ospedale Koelliker, Torino, Italy.
- 7SSD Dermatologia, Ospedale degli Infermi, Biella, Italy.
- 8SC Dermatologia, S. Andrea Hospital, ASL Vercelli, Vercelli, Italy.
- 9SSD Dermatologia, Cardinal Massaia Hospital, Asti, Italy.
- 10Department of Health Science, University of Eastern Piedmont, Novara, Italy.
Abstract
Introduction
Chronic plaque psoriasis is commonly treated with IL-17 and IL-23 inhibitors, which are highly effective but associated with substantial costs. Because many patients achieve long-term disease control, fixed-dose regimens may result in overtreatment.Objectives
This study assessed the economic impact of disease-activity-guided dose reduction (DR) strategies using secukinumab, brodalumab, guselkumab, and risankizumab in adults with stable plaque psoriasis.Methods
This cost analysis was based on data from the PSORED trial, a multicenter prospective open-label study conducted in Piedmont, Italy (2023-2025). Patients with stable disease (PASI ≤3, DLQI ≤3 for ≥9 months) underwent DR trough a 1.5x extension of maintenance dosing intervals. Costs under DR and standard dosing (SD) were compared over 52 weeks using Italian tariff data and real-world treatment patterns.Results
Among 156 enrolled patients, 39 discontinued DR, 38 returned to standard dosing, and one switched therapy. DR reduced biologics consumption without increasing follow-up requirements, yielding a 26% decrease in total costs and an average annual saving of €7,303.57 per patient.Conclusions
DR was both clinically effective and cost-saving, maintaining disease control without major safety concerns. These findings support the implementation of DR strategies in routine clinical practice to enhance long-term sustainability while preserving therapeutic efficacy.
Related
- JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series
- Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates
- Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis☆
- Exploring Dietary Supplements for Psoriasis Management: A Narrative Review
- Food-Derived Substances and Edible Chinese Medicinal Materials in Psoriasis Management: Potential, Evidence, and Perspectives-A Narrative Review.
BibTeX
@article{cammarata2026less,
title = {{Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.}},
author = {Edoardo Cammarata and Chiara Airoldi and Jacopo Colombo and Andrealuna Ucciero and Luca Mastorino and Veronica Arese and Lorenza Burzi and Franco Castelli and Massimo Chiarpenello and Francesca Graziola and Claudia Leporati and Michela Ortoncelli and Paolo Pella and Ginevra Pertusi and Alessia Pisterna and Pietro Quaglino and Simone Ribero and Gianluca Rossotto and Rossana Tiberio and Paolo Dapavo and Paola Savoia},
journal = {Dermatology practical \& conceptual},
year = {2026},
month = jul,
doi = {10.5826/dpc.1603a6747},
url = {https://europepmc.org/article/MED/42858399},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
AU - Edoardo Cammarata
AU - Chiara Airoldi
AU - Jacopo Colombo
AU - Andrealuna Ucciero
AU - Luca Mastorino
AU - Veronica Arese
AU - Lorenza Burzi
AU - Franco Castelli
AU - Massimo Chiarpenello
AU - Francesca Graziola
AU - Claudia Leporati
AU - Michela Ortoncelli
AU - Paolo Pella
AU - Ginevra Pertusi
AU - Alessia Pisterna
AU - Pietro Quaglino
AU - Simone Ribero
AU - Gianluca Rossotto
AU - Rossana Tiberio
AU - Paolo Dapavo
AU - Paola Savoia
PY - 2026
DA - 2026/07/31
JO - Dermatology practical & conceptual
DO - 10.5826/dpc.1603a6747
UR - https://europepmc.org/article/MED/42858399
AB - Introduction Chronic plaque psoriasis is commonly treated with IL-17 and IL-23 inhibitors, which are highly effective but associated with substantial costs. Because many patients achieve long-term disease control, fixed-dose regimens may result in overtreatment.Objectives This study assessed the economic impact of disease-activity-guided dose reduction (DR) strategies using secukinumab, brodalumab, guselkumab, and risankizumab in adults with stable plaque psoriasis.Methods This cost analysis was based on data from the PSORED trial, a multicenter prospective open-label study conducted in Piedmont, Italy (2023-2025). Patients with stable disease (PASI ≤3, DLQI ≤3 for ≥9 months) underwent DR trough a 1.5x extension of maintenance dosing intervals. Costs under DR and standard dosing (SD) were compared over 52 weeks using Italian tariff data and real-world treatment patterns.Results Among 156 enrolled patients, 39 discontinued DR, 38 returned to standard dosing, and one switched therapy. DR reduced biologics consumption without increasing follow-up requirements, yielding a 26% decrease in total costs and an average annual saving of €7,303.57 per patient.Conclusions DR was both clinically effective and cost-saving, maintaining disease control without major safety concerns. These findings support the implementation of DR strategies in routine clinical practice to enhance long-term sustainability while preserving therapeutic efficacy.
SN - 2160-9381
ER -